Portal de Periódicos da CAPES

Decoding the glycoproteome: a new frontier for biomarker discovery in cancer

2024; BioMed Central; Volume: 17; Issue: 1 Linguagem: Inglês

10.1186/s13045-024-01532-x

1756-8722

Kai He, Maryam Baniasad, Hyunwoo Kwon, Tomislav Čaval, Gege Xu, Carlito B. Lebrilla, Daniël W. Hommes, Carolyn R. Bertozzi,

Cancer Genomics and Diagnostics

Abstract Cancer early detection and treatment response prediction continue to pose significant challenges. Cancer liquid biopsies focusing on detecting circulating tumor cells (CTCs) and DNA (ctDNA) have shown enormous potential due to their non-invasive nature and the implications in precision cancer management. Recently, liquid biopsy has been further expanded to profile glycoproteins, which are the products of post-translational modifications of proteins and play key roles in both normal and pathological processes, including cancers. The advancements in chemical and mass spectrometry-based technologies and artificial intelligence-based platforms have enabled extensive studies of cancer and organ-specific changes in glycans and glycoproteins through glycomics and glycoproteomics. Glycoproteomic analysis has emerged as a promising tool for biomarker discovery and development in early detection of cancers and prediction of treatment efficacy including response to immunotherapies. These biomarkers could play a crucial role in aiding in early intervention and personalized therapy decisions. In this review, we summarize the significant advance in cancer glycoproteomic biomarker studies and the promise and challenges in integration into clinical practice to improve cancer patient care.